Safety and Efficacy Study of Several Replagal Dosing Regimens on Cardiac Function in Adults With Fabry Disease

• ClinicalTrials.gov Identifier: NCT00864851
• Recruitment Status: Completed
• First Posted: March 19, 2009
• Results First Posted: June 6, 2014
• Last Update Posted: June 9, 2021
• Sponsor: Shire
• Information provided by (Responsible Party): Takeda ( Shire )

Study Description

Brief Summary:

The purpose of this study is to compare the safety and effectiveness of various doses of Replagal in patients with cardiomyopathy due to Fabry disease.

Condition or disease	Intervention/treatment	Phase
Fabry Disease	Biological: Replagal	Phase 3

Detailed Description:

Fabry disease is an inherited, metabolic disease caused by mutations in the GALA gene. Patients with Fabry disease accumulate a complex glycosphingolipid named globotriaosylceramide (Gb3) in various tissues and organs. All organs are affected in Fabry disease but the majority of the morbidity and mortality are caused by cardiac, renal and neurological dysfunction. Accumulation of Gb3 in the heart causes hypertrophic cardiomyopathy, valvular abnormalities, arrhythmias and infarctions. Replagal has been shown to reduce Gb3 from key tissues and organs, and stabilize renal function in patients with Fabry disease. Evidence suggests that Replagal reduces left ventricular mass (LVM) and improves midwall fractional shortening (MFS) of the heart. Left ventricular hypertrophy is a major cause of morbidity and mortality in patients with Fabry disease.

This is a study of the safety and effectiveness of 3 dosing regimens of Replagal in adult patients with left ventricular hypertrophy due to Fabry disease.

The primary objective of the study is to compare the effects of 2 dosing regimens of Replagal (0.2 mg/kg IV every other week and 0.2 mg/kg IV weekly) on the reduction of left ventricular mass as measured by echocardiography.

The secondary objectives of this study are to compare the effects of 2 dosing regimens of Replagal (0.2 mg/kg IV every other week and 0.2 mg/kg IV weekly) on each of the following: exercise tolerance; improvement in disease-specific quality of life in heart failure patients; improvement of heart failure symptoms; magnitude of reduction in Gb3; rate of decline in renal function and improvement in the severity of proteinuria/albuminuria; and safety.

An alternative treatment regimen of 0.4 mg/kg Replagal IV weekly will also be explored but without formal comparison to the 0.2 mg/kg regimens. The investigation of the safety and efficacy of the 0.4 mg/kg IV weekly regimen is a secondary objective of this study.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 44 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Multi-Center, Open-Label, Randomized Study Evaluating the Safety and Efficacy of Three Dosing Regimens of Replagal Enzyme Replacement Therapy in Adult Patients With Fabry Disease
• Actual Study Start Date: December 29, 2008
• Actual Primary Completion Date: June 1, 2012
• Actual Study Completion Date: July 5, 2012

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: Replagal 0.2 mg/kg, IV, every other week; Patients randomized to receive Replagal 0.2 mg/kg via intravenous infusion every other week for 52 weeks.	Biological: Replagal; Intravenous (IV) infusion for 12 months; Other Name: algasidase alfa
Active Comparator: Replagal 0.2 mg/kg, IV, weekly; Patients randomized to receive Replagal 0.2 mg/kg via intravenous infusion every week for 52 weeks.	Biological: Replagal; Intravenous (IV) infusion for 12 months; Other Name: algasidase alfa
Active Comparator: Replagal 0.4 mg/kg, IV, weekly; Patients randomized to receive Replagal 0.4 mg/kg via intravenous infusion every week for 52 weeks.	Biological: Replagal; Intravenous (IV) infusion for 12 months; Other Name: algasidase alfa

Outcome Measures

Primary Outcome Measures :

1. Change From Baseline to Month 12 in Left Ventricular Mass Indexed to Height (LVMI) [ Time Frame: Baseline, Month 12 (Week 53) ]
   Left ventricular mass (LVM) was measured through echocardiography.

Secondary Outcome Measures :

1. Change From Baseline to Month 12 in Maximal Oxygen Consumption (VO2 Max) at Peak Exercise [ Time Frame: Baseline, Month 12 (Week 53) ]
   Exercise tolerance as measured by VO2 max at peak exercise using the standard exponential exercise protocol (STEEP).
2. Change From Baseline to Month 12 in Distance Walked in 6-Minute Walk Test (6MWT) [ Time Frame: Baseline, Month 12 (Week 53) ]
   Exercise tolerance using the 6MWT was measured as the total distance walked in 6 minutes.
3. Change From Baseline to Month 12 in the Minnesota Living With Heart Failure Questionnaire (MLHF-Q) Summary Score [ Time Frame: Baseline, Month 12 (Week 53) ]
   Quality of life (QoL) was evaluated using the MLHF-Q, version 2. The questionnaire is designed to assess the degree to which heart failure symptoms affect a patient's daily life. The summary score ranges from 0 to 105, with a score of 105 representing the highest adverse impact on a patient's QoL.
4. Change From Baseline to Month 12 in New York Heart Association (NYHA) Functional Class [ Time Frame: Baseline, Month 12 (Week 53) ]
   The NYHA functional classification system relates symptoms to everyday activities and the patient's quality of life. NYHA Classification - The Stages of Heart Failure: Class I (Mild): No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, or dyspnea (shortness of breath). Class II (Mild): Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in fatigue, palpitation, or dyspnea. Class III (Moderate): Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes fatigue, palpitation, or dyspnea. Class IV (Severe): Unable to carry out any physical activity without discomfort. Symptoms of cardiac insufficiency at rest. If any physical activity is undertaken, discomfort is increased.
5. Change From Baseline to Month 12 in Plasma Globotriaosylceramide (GB3) [ Time Frame: Baseline, Month 12 (Week 53) ]
6. Change From Baseline to Month 12 in Estimated Glomerular Filtration Rate (eGFR) [ Time Frame: Baseline, Month 12 (Week 53) ]
   Renal function was assessed by an evaluation of change from baseline to Month 12 in eGFR as calculated using the Modification of Diet for Renal Disease (MDRD) equation.
7. Change From Baseline to Month 12 in Urinary Albumin/Creatinine (A/Cr) Ratio [ Time Frame: Baseline, Month 12 (Week 53) ]
8. Safety Evaluation [ Time Frame: 56 Weeks ]
   Adverse events were collected throughout the study, from the time of informed consent to approximately 30 days post-final infusion.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• >18 years-old;
• Male:Fabry disease confirmed by deficiency of alfa galactosidase A activity OR Female:Fabry disease confirmed by a mutation of the alfa galactosidase A gene;
• ERT-naïve;
• LVM/h > 50g/m2.7 for males and >47 g/m2.7 for females;
• Negative pregnancy test at enrollment and contraception use required throughout study for female patients;
• Signed informed consent;

Exclusion Criteria:

• Class IV heart failure;
• Clinically significant hypertension;
• Hemodynamically significant valvular stenosis or regurgitation;
• Morbid obesity;
• Known autosomal dominant sarcoplasmic contractile protein gene mutation;
• Treatment with any investigational drug or device within the 30 days;
• Unable to comply with the protocol as determined by the Investigator;
• Positive for hepatitis B, hepatitis C or HIV

Contacts and Locations

Locations

United States, Arizona

AKDHC Tucson Access Center

Tucson, Arizona, United States, 85719

United States, Iowa

University of Iowa Hospitals and Clinics

Iowa City, Iowa, United States, 52242

United States, New York

New York Unversity School of Medicine

New York, New York, United States, 10016

United States, Virginia

O & O Alpan, LLC

Springfield, Virginia, United States, 22152

Australia, Victoria

The Royal Melbourne Hospital

Parkville, Victoria, Australia, 3052

Czechia

The Charles University Hospital

Prague, Czechia, 128 OO

Finland

Turku University Central Hospital

Turku, Finland, FI-20520

Paraguay

Gobemador Irala y Coronel Lopez - Barrio Sojania

Asuncion, Paraguay

Poland

Szpital Uniwersytecki w Krakowie

Krakow, Poland, 31-066

Instytut Kardiologii

Warsaw, Poland, 04-628

Slovenia

General Hospital Slovenj Gradec

Slovenj Gradec, Slovenia, SI 2380

United Kingdom

Salford Royal NHS Foundation Trust

Salford, United Kingdom, M6 8HD

Sponsors and Collaborators

Shire

Investigators

• Study Director: Study Director; Takeda

More Information

Publications of Results:

Malek LA, Chojnowska L, Spiewak M, Klopotowski M, Misko J, Petryka J, Milosz B, Ruzyllo W. Cardiac magnetic resonance imaging in patients with Fabry's disease. Kardiol Pol. 2010 Aug;68(8):929-34.

• Responsible Party: Shire
• ClinicalTrials.gov Identifier: NCT00864851
• Other Study ID Numbers: TKT028; 2007-005543-22 ( EudraCT Number )
• First Posted: March 19, 2009
• Results First Posted: June 6, 2014
• Last Update Posted: June 9, 2021
• Last Verified: May 2021

Additional relevant MeSH terms:

Fabry Disease; Sphingolipidoses; Lysosomal Storage Diseases, Nervous System; Brain Diseases, Metabolic, Inborn; Brain Diseases, Metabolic; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Cerebral Small Vessel Diseases; Cerebrovascular Disorders; Vascular Diseases; Cardiovascular Diseases; Genetic Diseases, X-Linked; Genetic Diseases, Inborn; Metabolism, Inborn Errors; Lipidoses; Lipid Metabolism, Inborn Errors; Lysosomal Storage Diseases; Metabolic Diseases; Lipid Metabolism Disorders